Skip to main content

Table 2 Demographic data, patient clinical characteristics, site of infection and microorganisms identified

From: Evaluation of a protocol for vancomycin administration in critically patients with and without kidney dysfunction

  GROUP A GROUP B
N. of patients 210 138
Gender male. n. (%) 153 (73) 95 (69)
Age (year) 63.0 ± 11.2 70.6 ± 9.9*
BMI (Kg/m2) 27.2 ± 6.3 26.0 ± 5.6
Basal Serum creatinine (mg/L) 1.0 ± 0.4 2.3 ± 1.4*
Basal Creatinine Clearance (ml/min/1.73 m2) 106.4 ± 40.7 37 ± 16.2*
Loading dose (mg/kg) 16.7 ± 4.8 18 ± 2
Mean time to first VSC (hours) 40 ± 3 41 ± 2
Total continuous infusion dosea (g) 5.4 ± 0.3 3.6 ± 0.8*
Duration of vancomycin therapy (days) 9.0 ± 1.1 9.1 ± 1.6
Nephrotoxicity n. (%) 5 (2.4) 13 (9.4)
Concomitant use of nephrotoxic agents:
Vasopressor n. (%) 32 (15.2) 25 (18.1)
Aminoglycoside. n. (%) 12 (5.7) 9 (6.5)
Ace inhibitor n. (%) 41 (19.5) 21 (15.2)
Type of patient at ICU admission:   
Medical n. (%) 119 (56.7) 69 (50.0)
Urgent surgery n. ( %) 7 (3.3) 23 (16.6)*
Scheduled surgery n.(%) 84 (40.0) 46 (33.4)
Admission diagnosis. n. (%)   
Sepsis 63 (30 %) 36 (26)
Respiratory failure without sepsis 43 (20.4) 26 (18.8)
Post surgery 80 (38) 66 (47.8)
Other 24 (11.4) 10 (7.2)
SAPS II (first 24 h) 40.3 ± 8.0 46.2 ± 7.7*
ICU deaths. n. (%) 45 (21.4) 33 (23.9)
Site of infection. n.( %)   
Low Respiratory Tract 102 (48.6) 50 (36.2)*
Intra-abdominal 43 (20.5) 44 (31.8)*
Bloodstream 30 (14.3) 6 (4.3)*
Skin and soft tissue 23 (10.9) 38 (27.5)*
Other 12 (5.7) 0*
Microorganisms identified. n. (%)   
Staphylococci spp 133 (63.3) 86 (62.3)
Enterococci spp 74 (35.2) 52 (37.7)
Streptococci spp 3 ( 1.4) 0
Vancomycin AUC/ MIC at first determination 468 ± 79 490 ± 84
  1. Continuous variables are reported as mean ± standard deviation (SD); * p<0.05
  2. BMI: Body Mass Index
  3. a Total infusion of vancomycin dose until first determination (included loading dose)